LLAI Lunglife Ai Inc

TIDMLLAI

LungLife AI, INC

12 October 2021

LungLife AI, Inc.

(the "Company" or "LungLife")

PLA Code application submitted in first step in reimbursement process

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical Association.

Reimbursement in the US is comprised of three components: code, price, and coverage. The code is the mechanism by which clinical laboratories can more specifically identify their tests when billing Medicare and commercial insurers. If LungLife's application for a PLA code is granted, the code will be priced for Medicare by the Centers for Medicare & Medicaid Services (CMS) in 2022. PLA code applications can be made at four times in the year.

For further information please contact:

 
LungLife AI, Inc.                                                           www.lunglifeai.com 
Paul Pagano, CEO                                                               Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                  Tel: +44 (0)20 7597 5970 
 & Broker) 
Daniel Adams / Virginia Bull / Cameron 
 MacRitchie 
 
Walbrook PR Limited                      Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings                               Mob: 07980 541 893 / 07407 804 654 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABCBDGBDBDGBB

(END) Dow Jones Newswires

October 12, 2021 02:00 ET (06:00 GMT)

Lunglife Ai (LSE:LLAI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Lunglife Ai (LSE:LLAI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024